Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Korosho to Promote Studies to Set Pediatric Doses
March 19, 2001
- Chuikyo Approves 3 New Advanced Medical Technologies
March 19, 2001
- Control Achieved in More than 65% of RA Patients in Long-term Outpatient Care: RDIC Seminar
March 19, 2001
- Notification Issued on ICH Stability Test Guidelines
March 19, 2001
- Significance of Genomic Base Sequence Other than Gene Code Should Be Studied: Prof. Shimizu
March 19, 2001
- REGULATORY NEWS IN BRIEF -1-
March 19, 2001
- PMSB to Issue Notification on Safety Management of Medical Radiation
March 19, 2001
- REGULATORY NEWS IN BRIEF -2-
March 19, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
March 19, 2001
- Number of Elderly Outpatients Decreases Since January: Hodanren Survey
March 19, 2001
- WORLD NEWS IN BRIEF -1-
March 19, 2001
- Kyoritsu College of Pharmacy to Open Pharmacy
March 19, 2001
- WORLD NEWS IN BRIEF -2-
March 19, 2001
- Measures Taken to Prevent Medical Errors Reported: Safety Seminar
March 19, 2001
- Adsorption Type Hemocatharsis Device Designated as Orphan Device
March 19, 2001
- Over 90% of Nursing Staff Have Committed or Nearly Committed Errors
March 12, 2001
- Japan Tobacco to Make Pharma Business Profitable in FY2005
March 12, 2001
- BUSINESS NEWS IN BRIEF -2-
March 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 12, 2001
- Dainippon to Report Record-high Sales, Profits Again: President Miyatake
March 12, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…